Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744257 | 1.00 | HCAR2 (0.51) | HCAR2NPC1RAB9ACHRM4BCHE | |
| SCHEMBL23744723 | 0.94 | HCAR2 (0.47) | HCAR2NPC1RAB9ACHRM4CHRM2 | |
| SCHEMBL23744451 | 0.92 | HCAR2 (0.44) | HCAR2NPC1RAB9ACHRM4BCHE | |
| SCHEMBL23744742 | 0.92 | HCAR2 (0.46) | HCAR2NPC1RAB9ACHRM4HDAC1 | |
| SCHEMBL23744486 | 0.90 | HCAR2 (0.42) | HCAR2CHRM4BCHE | |
| SCHEMBL23744584 | 0.90 | HCAR2 (0.42) | HCAR2CHRM4BCHE | |
| SCHEMBL23744636 | 0.89 | CHRM2 (0.46) | HCAR2CHRM4CHRM2CHRM1 | |
| SCHEMBL26429431 | 0.87 | HCAR2 (0.49) | HCAR2NPC1RAB9ACHRM4CHRM2 | |
| SCHEMBL26429430 | 0.87 | HCAR2 (0.49) | HCAR2NPC1RAB9ACHRM4CHRM2 | |
| SCHEMBL23744724 | 0.86 | CHRM2 (0.39) | HCAR2CHRM4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HCAR2 76/4885NPC1 1236/4885RAB9A 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.